Bone (Mineral) Density Studies
|
|
- Hugo Banks
- 6 years ago
- Views:
Transcription
1 Bone (Mineral) Density Studies Policy Number: Original Effective Date: MM /23/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/28/2017 Section: Radiology Place(s) of Service: Outpatient I. Description A bone mineral density (BMD) study is a non-invasive technique that is used to measure bone mineral content and bone mineral density. Its primary role is to detect osteoporosis and to predict the risk of fractures. Osteoporosis is a disease that results in the loss of bone mineral content or bone density. This leads to thinning and weakening of bones, increasing the risk of fractures. BMD can be measured with a variety of techniques in a variety of sites that are subdivided into central (hip or spine) and peripheral (wrist, finger or heel). Dual x-ray absorptiometry (DXA) is the most commonly used technique for BMD measurements. Ultrasound (US) densitometry is as an office based technology for measuring BMD at peripheral sites, mainly the heel. Peripheral measurements can identify patients with low bone mass, but cannot predict response to pharmacologic therapy and is not a substitute for central BMD measurements. Therefore, central BMD measurements are recommended for the initial diagnosis and for repeat BMD measurements. This policy does not apply to CPT 77078: Computed tomography, bone mineral density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine). Criteria and guidelines can be found on the National Imaging Associates website at II. Criteria/Guidelines A. An initial BMD study of the hip and/or spine is covered (subject to Limitations and Administrative Guidelines) to assess fracture risk and the need for pharmacologic therapy in the following individuals considered to be at high-risk for osteoporosis: 1. Women 65 years of age or older and men 70 years of age or older 2. Postmenopausal women with any of the following risk factors: a. History of a low-impact fracture* after age 45 in a first-degree relative b. Body weight of less than 127 lbs. or BMI of 20 or less c. Current smoker d. Surgical or natural menopause before age 40
2 Bone Mineral Density Studies 2 3. Premenopausal women with documented hypo-estrogenic amenorrhea for more than one year 4. Men or women with the following chronic conditions known to be associated with bone loss: a. Cushing's syndrome b. Male hypogonadism for more than five years c. Hyperthyroidism d. Hyperparathyroidism e. Ankylosing spondylitis f. Rheumatoid arthritis g. Systemic lupus erythematosus h. Leukemia i. Multiple myeloma j. Chronic kidney disease (stages III, IV and V) k. Celiac disease l. Prolonged severe loss of mobility (unable to ambulate outside of one's dwelling without a wheelchair for more than one year) 5. Patients taking any of the following medications associated with bone loss: a. Anticonvulsants b. Oral glucocorticoids for more than three months at a dose equivalent to 5 mg of prednisone or greater per day c. Aromatase inhibitors d. Chemotherapy agents (i.e., methotrexate or other antimetabolites) e. Depo-medroxy progesterone acetate (Depo-Provera) when used for more than two years f. Gonadotropin-releasing hormone (GnRH) agonists (buserelin, leuprolide, nafarelin) 6. Solid organ or allogeneic bone marrow transplant recipients 7. Patients with osseous abnormalities shown on imaging studies indicative of osteoporosis, osteopenia or a vertebral compression fracture (defined as vertebral body height loss of 20% or more) 8. Adults who have had a documented low-impact fracture (excluding fingers and toes) 9. Children with a disease or condition associated with bone loss or on prolonged medications that are known to decrease bone mass B. Peripheral BMD studies are covered (subject to Limitations/Exclusions and Administrative Guidelines) if the hip/spine cannot be done or the patient is over the table limit for weight. A low-impact fracture is defined as a fracture occurring spontaneously or from a fall from standing height, including fractures from activities such as a cough, sneeze or abrupt movement (e.g., opening a window).
3 Bone Mineral Density Studies 3 III. Limitations/Exclusions A. Routine BMD screening for osteoporosis is not recommended for women under the age of 65 and for men under the age of 70. B. Repeat central BMD studies are limited to one every two years (23 months must past since the previous BMD study) for patients whose last scan showed osteopenia/osteoporosis. C. Repeat central BMD studies for individuals who previously tested normal may be retested no sooner than three years from the last BMD if they continue to meet the criteria listed above. D. Repeat central BMD studies performed more frequently than once every two years are limited to individuals currently taking an aromatase inhibitor or on glucocorticoid therapy equivalent to 5.0 mg or more of prednisone per day for more than three months. E. A follow up DXA is not covered when used to confirm a diagnosis obtained by an US or QCT. F. Clinicians are encouraged to use the same facility and same scanner for initial and follow-up BMD studies whenever possible for greater consistency. G. Dual Photon Absorptiometry (DPA) and images obtained during a BMD study (e.g., rapid vertebral assessment) are not covered. H. 3D reconstruction is not covered for BMD studies. IV. Administrative Guidelines A. Precertification is required for the following: 1. Patients under the age of 18. To precertify, please complete HMSA's Precertification Request and mail or fax the form, or use iexchange as indicated. The request must include supporting documentation from the patient's medical records with the high-risk indications that would justify a BMD study as well as the proposed therapy for the patient. 2. For follow-up studies performed more frequently than once every two years. Requests must include the previous BMD study results, other pertinent test findings and a list of medications the patient is currently taking. B. Compliance with the provisions in this policy is subject to monitoring, post payment data analysis, and subsequent medical review. The following documentation should be kept in the patient's medical records and made available upon request: 1. Clinical indications to substantiate that the test is reasonable and necessary. 2. Physician s order signed (not rubber-stamped) and dated (mm/dd/yy). 3. The diagnostic evaluation documenting symptoms, other diagnostic X-rays, and physical exam findings must have been dated at a time reasonably proximate to the scan. 4. The name and medication regimen for patients undergoing drug therapy. C. If a patient does not meet HMSA s guidelines for coverage but has indicated that he or she wants the services performed despite noncoverage, the patient should be asked to sign HMSA's Agreement of Financial Responsibility. A signed waiver indicates that the patient will be responsible for the denied charges. D. When submitting a claim for a BMD study that does not meet HMSA guidelines, append modifier code GA to the CPT code for the service. The use of the GA modifier will alert HMSA
4 Bone Mineral Density Studies 4 that the claim should be processed to indicate that the patient will be financially responsible for the service, and that the noncovered charges should not be a provider adjustment. E. The signed waiver should be kept in the patient's record. HMSA reserves the right to conduct periodic audits on claims submitted with the GA modifier and review medical records for signed waivers for this service. F. The following codes are provided for informational purposes only. Inclusion/exclusion of a procedure or diagnosis does not constitute or imply coverage or provider reimbursement: Applicable CPT codes: CPT Code Description Ultrasound bone density measurement and interpretation, peripheral site(s), any method Dual energy X-ray absorptiometry (DXA), bone density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine) appendicular skeleton (peripheral) (e.g., radius, wrist, heel) Codes that do not meet payment determination criteria: CPT code Description Dual-energy x-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine), including vertebral fracture assessment Vertebral fracture assessment via dual-energy x-ray absorptiometry (DXA) Bone density (bone mineral content) study, one or more sites; single photon absorptiometry Bone density (bone mineral content) study, one or more sites; dual photon absorptiometry, one or more sites HCPCS Code G0130 Applicable ICD-10 codes: Description Single energy X-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel) ICD-10 Code Description E21.0 Primary hyperparathyroidism E21.1 Secondary hyperparathyroidism, not elsewhere classified E21.2 Other hyperparathyroidism E21.3 Hyperparathyroidism, unspecified E24.0 Pituitary-dependent Cushing's disease
5 Bone Mineral Density Studies 5 E24.2 Drug-induced Cushing's syndrome E24.3 Ectopic ACTH syndrome E24.4 Alcohol-induced pseudo-cushing's syndrome E24.8 Other Cushing's syndrome E24.9 Cushing's syndrome, unspecified E Symptomatic premature menopause E Asymptomatic premature menopause E28.39 Other primary ovarian failure E89.40 Asymptomatic postprocedural ovarian failure E89.41 Symptomatic postprocedural ovarian failure G Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status G Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status G Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status G Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status G Localization-related (focal) (partial) symptomatic epilepsy and epileptic
6 Bone Mineral Density Studies 6 syndromes with complex partial seizures, intractable, without status G Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status G Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status G Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status G Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status G Other generalized epilepsy and epileptic syndromes, not intractable, with status G Other generalized epilepsy and epileptic syndromes, not intractable, without status G Other generalized epilepsy and epileptic syndromes, intractable, with status G Other generalized epilepsy and epileptic syndromes, intractable, without status G Epileptic seizures related to external causes, not intractable, with status G Epileptic seizures related to external causes, not intractable, without status G Other epilepsy, not intractable, with status G Other epilepsy, not intractable, without status G Other epilepsy, intractable, with status G Other epilepsy, intractable, without status G Lennox-Gastaut syndrome, not intractable, with status G Lennox-Gastaut syndrome, not intractable, without status G Lennox-Gastaut syndrome, intractable, with status G Lennox-Gastaut syndrome, intractable, without status G Epileptic spasms, not intractable, with status G Epileptic spasms, not intractable, without status G Epileptic spasms, intractable, with status G Epileptic spasms, intractable, without status G40.89 Other seizures G Epilepsy, unspecified, not intractable, with status G Epilepsy, unspecified, not intractable, without status G Epilepsy, unspecified, intractable, with status G Epilepsy, unspecified, intractable, without status G40.A01 Absence epileptic syndrome, not intractable, with status G40.A09 Absence epileptic syndrome, not intractable, without status G40.A11 Absence epileptic syndrome, intractable, with status
7 Bone Mineral Density Studies 7 G40.A19 Absence epileptic syndrome, intractable, without status G40.B01 Juvenile myoclonic epilepsy, not intractable, with status G40.B09 Juvenile myoclonic epilepsy, not intractable, without status G40.B11 Juvenile myoclonic epilepsy, intractable, with status G40.B19 Juvenile myoclonic epilepsy, intractable, without status K90.0 Celiac disease M05.40 Rheumatoid myopathy with rheumatoid arthritis of unspecified site M Rheumatoid myopathy with rheumatoid arthritis of right shoulder M Rheumatoid myopathy with rheumatoid arthritis of left shoulder M Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder M Rheumatoid myopathy with rheumatoid arthritis of right elbow M Rheumatoid myopathy with rheumatoid arthritis of left elbow M Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow M Rheumatoid myopathy with rheumatoid arthritis of right wrist M Rheumatoid myopathy with rheumatoid arthritis of left wrist M Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist M Rheumatoid myopathy with rheumatoid arthritis of right hand M Rheumatoid myopathy with rheumatoid arthritis of left hand M Rheumatoid myopathy with rheumatoid arthritis of unspecified hand M Rheumatoid myopathy with rheumatoid arthritis of right hip M Rheumatoid myopathy with rheumatoid arthritis of left hip M Rheumatoid myopathy with rheumatoid arthritis of unspecified hip M Rheumatoid myopathy with rheumatoid arthritis of right knee M Rheumatoid myopathy with rheumatoid arthritis of left knee M Rheumatoid myopathy with rheumatoid arthritis of unspecified knee M Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot M Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot M Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot M05.49 Rheumatoid myopathy with rheumatoid arthritis of multiple sites M05.50 Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site M Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder M Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow M Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist
8 Bone Mineral Density Studies 8 M Rheumatoid polyneuropathy with rheumatoid arthritis of right hand M Rheumatoid polyneuropathy with rheumatoid arthritis of left hand M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand M Rheumatoid polyneuropathy with rheumatoid arthritis of right hip M Rheumatoid polyneuropathy with rheumatoid arthritis of left hip M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip M Rheumatoid polyneuropathy with rheumatoid arthritis of right knee M Rheumatoid polyneuropathy with rheumatoid arthritis of left knee M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee M Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot M Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot M Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot M05.59 Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites M05.70 Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement
9 Bone Mineral Density Studies 9 M Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement M Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement M05.79 Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement M05.80 Other rheumatoid arthritis with rheumatoid factor of unspecified site M Other rheumatoid arthritis with rheumatoid factor of right shoulder M Other rheumatoid arthritis with rheumatoid factor of left shoulder M Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder M Other rheumatoid arthritis with rheumatoid factor of right elbow M Other rheumatoid arthritis with rheumatoid factor of left elbow M Other rheumatoid arthritis with rheumatoid factor of unspecified elbow M Other rheumatoid arthritis with rheumatoid factor of right wrist M Other rheumatoid arthritis with rheumatoid factor of left wrist M Other rheumatoid arthritis with rheumatoid factor of unspecified wrist M Other rheumatoid arthritis with rheumatoid factor of right hand M Other rheumatoid arthritis with rheumatoid factor of left hand M Other rheumatoid arthritis with rheumatoid factor of unspecified hand M Other rheumatoid arthritis with rheumatoid factor of right hip M Other rheumatoid arthritis with rheumatoid factor of left hip M Other rheumatoid arthritis with rheumatoid factor of unspecified hip M Other rheumatoid arthritis with rheumatoid factor of right knee M Other rheumatoid arthritis with rheumatoid factor of left knee M Other rheumatoid arthritis with rheumatoid factor of unspecified knee M Other rheumatoid arthritis with rheumatoid factor of right ankle and foot M Other rheumatoid arthritis with rheumatoid factor of left ankle and foot M Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot M05.89 Other rheumatoid arthritis with rheumatoid factor of multiple sites
10 Bone Mineral Density Studies 10 M05.9 Rheumatoid arthritis with rheumatoid factor, unspecified M06.00 Rheumatoid arthritis without rheumatoid factor, unspecified site M Rheumatoid arthritis without rheumatoid factor, right shoulder M Rheumatoid arthritis without rheumatoid factor, left shoulder M Rheumatoid arthritis without rheumatoid factor, unspecified shoulder M Rheumatoid arthritis without rheumatoid factor, right elbow M Rheumatoid arthritis without rheumatoid factor, left elbow M Rheumatoid arthritis without rheumatoid factor, unspecified elbow M Rheumatoid arthritis without rheumatoid factor, right wrist M Rheumatoid arthritis without rheumatoid factor, left wrist M Rheumatoid arthritis without rheumatoid factor, unspecified wrist M Rheumatoid arthritis without rheumatoid factor, right hand M Rheumatoid arthritis without rheumatoid factor, left hand M Rheumatoid arthritis without rheumatoid factor, left hand M Rheumatoid arthritis without rheumatoid factor, unspecified hand M Rheumatoid arthritis without rheumatoid factor, right hip M Rheumatoid arthritis without rheumatoid factor, left hip M Rheumatoid arthritis without rheumatoid factor, unspecified hip M Rheumatoid arthritis without rheumatoid factor, right knee M Rheumatoid arthritis without rheumatoid factor, left knee M Rheumatoid arthritis without rheumatoid factor, unspecified knee M Rheumatoid arthritis without rheumatoid factor, right ankle and foot M Rheumatoid arthritis without rheumatoid factor, left ankle and foot M Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot M06.08 Rheumatoid arthritis without rheumatoid factor, vertebrae M06.09 Rheumatoid arthritis without rheumatoid factor, multiple sites M06.20 Rheumatoid bursitis, unspecified site M Rheumatoid bursitis, right shoulder M Rheumatoid bursitis, left shoulder M Rheumatoid bursitis, unspecified shoulder M Rheumatoid bursitis, right elbow M Rheumatoid bursitis, left elbow M Rheumatoid bursitis, unspecified elbow M Rheumatoid bursitis, right wrist M Rheumatoid bursitis, left wrist M Rheumatoid bursitis, unspecified wrist M Rheumatoid bursitis, right hand M Rheumatoid bursitis, left hand
11 Bone Mineral Density Studies 11 M Rheumatoid bursitis, unspecified hand M Rheumatoid bursitis, right hip M Rheumatoid bursitis, left hip M Rheumatoid bursitis, unspecified hip M Rheumatoid bursitis, right knee M Rheumatoid bursitis, left knee M Rheumatoid bursitis, unspecified knee M Rheumatoid bursitis, right ankle and foot M Rheumatoid bursitis, left ankle and foot M Rheumatoid bursitis, unspecified ankle and foot M06.28 Rheumatoid bursitis, vertebrae M06.29 Rheumatoid bursitis, multiple sites M06.30 Rheumatoid nodule, unspecified site M Rheumatoid nodule, right shoulder M Rheumatoid nodule, left shoulder M Rheumatoid nodule, unspecified shoulder M Rheumatoid nodule, right elbow M Rheumatoid nodule, left elbow M Rheumatoid nodule, unspecified elbow M Rheumatoid nodule, right wrist M Rheumatoid nodule, left wrist M Rheumatoid nodule, unspecified wrist M Rheumatoid nodule, right hand M Rheumatoid nodule, left hand M Rheumatoid nodule, unspecified hand M Rheumatoid nodule, right hip M Rheumatoid nodule, left hip M Rheumatoid nodule, unspecified hip M Rheumatoid nodule, right knee M Rheumatoid nodule, left knee M Rheumatoid nodule, unspecified knee M Rheumatoid nodule, right ankle and foot M Rheumatoid nodule, left ankle and foot M Rheumatoid nodule, unspecified ankle and foot M06.38 Rheumatoid nodule, vertebrae M06.39 Rheumatoid nodule, multiple sites M06.80 Other specified rheumatoid arthritis, unspecified site
12 Bone Mineral Density Studies 12 M Other specified rheumatoid arthritis, right shoulder M Other specified rheumatoid arthritis, left shoulder M Other specified rheumatoid arthritis, unspecified shoulder M Other specified rheumatoid arthritis, right elbow M Other specified rheumatoid arthritis, left elbow M Other specified rheumatoid arthritis, unspecified elbow M Other specified rheumatoid arthritis, right wrist M Other specified rheumatoid arthritis, left wrist M Other specified rheumatoid arthritis, unspecified wrist M Other specified rheumatoid arthritis, right hand M Other specified rheumatoid arthritis, left hand M Other specified rheumatoid arthritis, unspecified hand M Other specified rheumatoid arthritis, right hip M Other specified rheumatoid arthritis, left hip M Other specified rheumatoid arthritis, unspecified hip M Other specified rheumatoid arthritis, right knee M Other specified rheumatoid arthritis, left knee M Other specified rheumatoid arthritis, unspecified knee M Other specified rheumatoid arthritis, right ankle and foot M Other specified rheumatoid arthritis, left ankle and foot M Other specified rheumatoid arthritis, unspecified ankle and foot M06.88 Other specified rheumatoid arthritis, vertebrae M06.89 Other specified rheumatoid arthritis, multiple sites M06.9 Rheumatoid arthritis, unspecified M08.1 Juvenile ankylosing spondylitis M32.0 Drug-induced systemic lupus erythematosus M32.10 Systemic lupus erythematosus, organ or system involvement unspecified M32.11 Endocarditis in systemic lupus erythematosus M32.12 Pericarditis in systemic lupus erythematosus M32.13 Lung involvement in systemic lupus erythematosus M32.14 Glomerular disease in systemic lupus erythematosus M32.15 Tubulo-interstitial nephropathy in systemic lupus erythematosus M32.19 Other organ or system involvement in systemic lupus erythematosus M32.8 Other forms of systemic lupus erythematosus M32.9 Systemic lupus erythematosus, unspecified M45.0 Ankylosing spondylitis of multiple sites in spine M45.1 Ankylosing spondylitis of occipito-atlanto-axial region
13 Bone Mineral Density Studies 13 M45.2 Ankylosing spondylitis of cervical region M45.3 Ankylosing spondylitis of cervicothoracic region M45.4 Ankylosing spondylitis of thoracic region M45.5 Ankylosing spondylitis of thoracolumbar region M45.6 Ankylosing spondylitis lumbar region M45.7 Ankylosing spondylitis of lumbosacral region M45.8 Ankylosing spondylitis sacral and sacrococcygeal region M45.9 Ankylosing spondylitis of unspecified sites in spine M48.8x1 M48.8x2 M48.8x3 M48.8x4 M48.8x5 M48.8x6 M48.8x7 M48.8x8 M48.8x9 M80.00xA M80.00xD M80.00xG M80.00xK M80.00xP M80.00xS M80.031A M80.031D M80.031G M80.031K Other specified spondylopathies, occipito-atlanto-axial region Other specified spondylopathies, cervical region Other specified spondylopathies, cervicothoracic region Other specified spondylopathies, thoracic region Other specified spondylopathies, thoracolumbar region Other specified spondylopathies, lumbar region Other specified spondylopathies, lumbosacral region Other specified spondylopathies, sacral and sacrococcygeal region Other specified spondylopathies, site unspecified site, initial encounter for fracture site, subsequent encounter for fracture with routine healing site, subsequent encounter for fracture with delayed healing site, subsequent encounter for fracture with nonunion site, subsequent encounter for fracture with malunion site, sequela Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with routine healing Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with delayed healing Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with nonunion
14 Bone Mineral Density Studies 14 M80.031P M80.031S M80.032A M80.032D M80.032G M80.032K M80.032P M80.032S M80.039A M80.039D M80.039G M80.039K M80.039P M80.039S M80.80xA M80.80xD M80.80xG M80.80xK M80.80xP Age-related osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with malunion Age-related osteoporosis with current pathological fracture, right forearm, sequela Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with routine healing Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with delayed healing Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with nonunion Age-related osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with malunion Age-related osteoporosis with current pathological fracture, left forearm, sequela forearm, initial encounter for fracture forearm, subsequent encounter for fracture with routine healing forearm, subsequent encounter for fracture with delayed healing forearm, subsequent encounter for fracture with nonunion forearm, subsequent encounter for fracture with malunion forearm, sequela Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with routine healing Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with delayed healing Other osteoporosis with current pathological fracture, unspecified site, subsequent encounter for fracture with nonunion Other osteoporosis with current pathological fracture, unspecified site,
15 Bone Mineral Density Studies 15 M80.80xS M80.831A M80.831D M80.831G M80.831K M80.831P M80.831S M80.832A M80.832D M80.832G M80.832K M80.832P M80.832S M80.839A M80.839D M80.839G M80.839K M80.839P M80.839S subsequent encounter for fracture with malunion Other osteoporosis with current pathological fracture, unspecified site, sequela Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with routine healing Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with delayed healing Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with nonunion Other osteoporosis with current pathological fracture, right forearm, subsequent encounter for fracture with malunion Other osteoporosis with current pathological fracture, right forearm, sequela Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with routine healing Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with delayed healing Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with nonunion Other osteoporosis with current pathological fracture, left forearm, subsequent encounter for fracture with malunion Other osteoporosis with current pathological fracture, left forearm, sequela Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with routine healing Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with delayed healing Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with nonunion Other osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with malunion Other osteoporosis with current pathological fracture, unspecified forearm,
16 Bone Mineral Density Studies 16 sequela M81.0 Age-related osteoporosis without current pathological fracture M81.6 Localized osteoporosis [Lequesne] M81.8 Other osteoporosis without current pathological fracture M84.40xA Pathological fracture, unspecified site, initial encounter for fracture M84.40xD M84.40xG M84.40xK M84.40xP M84.40xS M84.431A M84.431D M84.431G M84.431K M84.431P M84.431S M84.432A M84.432D M84.432G M84.432K M84.432P M84.432S M84.433A M84.433D Pathological fracture, unspecified site, subsequent encounter for fracture with routine healing Pathological fracture, unspecified site, subsequent encounter for fracture with delayed healing Pathological fracture, unspecified site, subsequent encounter for fracture with nonunion Pathological fracture, unspecified site, subsequent encounter for fracture with malunion Pathological fracture, unspecified site, sequela Pathological fracture, right ulna, initial encounter for fracture Pathological fracture, right ulna, subsequent encounter for fracture with routine healing Pathological fracture, right ulna, subsequent encounter for fracture with delayed healing Pathological fracture, right ulna, subsequent encounter for fracture with nonunion Pathological fracture, right ulna, subsequent encounter for fracture with malunion Pathological fracture, right ulna, sequela Pathological fracture, left ulna, initial encounter for fracture Pathological fracture, left ulna, subsequent encounter for fracture with routine healing Pathological fracture, left ulna, subsequent encounter for fracture with delayed healing Pathological fracture, left ulna, subsequent encounter for fracture with nonunion Pathological fracture, left ulna, subsequent encounter for fracture with malunion Pathological fracture, left ulna, sequela Pathological fracture, right radius, initial encounter for fracture Pathological fracture, right radius, subsequent encounter for fracture with routine healing
17 Bone Mineral Density Studies 17 M84.433G M84.433K M84.433P M84.433S M84.434A M84.434D M84.434G M84.434K M84.434P M84.434S M84.439K M84.439P M84.439S M84.50xA M84.50xD M84.50xG M84.50xK M84.50xP M84.50xS M84.531A M84.531D Pathological fracture, right radius, subsequent encounter for fracture with delayed healing Pathological fracture, right radius, subsequent encounter for fracture with nonunion Pathological fracture, right radius, subsequent encounter for fracture with malunion Pathological fracture, right radius, sequela Pathological fracture, left radius, initial encounter for fracture Pathological fracture, left radius, subsequent encounter for fracture with routine healing Pathological fracture, left radius, subsequent encounter for fracture with delayed healing Pathological fracture, left radius, subsequent encounter for fracture with nonunion Pathological fracture, left radius, subsequent encounter for fracture with malunion Pathological fracture, left radius, sequela Pathological fracture, unspecified ulna and radius, subsequent encounter for fracture with nonunion Pathological fracture, unspecified ulna and radius, subsequent encounter for fracture with malunion Pathological fracture, unspecified ulna and radius, sequela Pathological fracture in neoplastic disease, unspecified site, initial encounter for fracture Pathological fracture in neoplastic disease, unspecified site, subsequent encounter for fracture with routine healing Pathological fracture in neoplastic disease, unspecified site, subsequent encounter for fracture with delayed healing Pathological fracture in neoplastic disease, unspecified site, subsequent encounter for fracture with nonunion Pathological fracture in neoplastic disease, unspecified site, subsequent encounter for fracture with malunion Pathological fracture in neoplastic disease, unspecified site, sequela Pathological fracture in neoplastic disease, right ulna, initial encounter for fracture Pathological fracture in neoplastic disease, right ulna, subsequent encounter for fracture with routine healing
18 Bone Mineral Density Studies 18 M84.531G M84.531K M84.531P M84.531S M84.532A M84.532D M84.532G M84.532K M84.532P M84.532S M84.533A M84.533D M84.533G M84.533K M84.533P M84.533S M84.534A M84.534D M84.534G M84.534K Pathological fracture in neoplastic disease, right ulna, subsequent encounter for fracture with delayed healing Pathological fracture in neoplastic disease, right ulna, subsequent encounter for fracture with nonunion Pathological fracture in neoplastic disease, right ulna, subsequent encounter for fracture with malunion Pathological fracture in neoplastic disease, right ulna, sequela Pathological fracture in neoplastic disease, left ulna, initial encounter for fracture Pathological fracture in neoplastic disease, left ulna, subsequent encounter for fracture with routine healing Pathological fracture in neoplastic disease, left ulna, subsequent encounter for fracture with delayed healing Pathological fracture in neoplastic disease, left ulna, subsequent encounter for fracture with nonunion Pathological fracture in neoplastic disease, left ulna, subsequent encounter for fracture with malunion Pathological fracture in neoplastic disease, left ulna, sequela Pathological fracture in neoplastic disease, right radius, initial encounter for fracture Pathological fracture in neoplastic disease, right radius, subsequent encounter for fracture with routine healing Pathological fracture in neoplastic disease, right radius, subsequent encounter for fracture with delayed healing Pathological fracture in neoplastic disease, right radius, subsequent encounter for fracture with nonunion Pathological fracture in neoplastic disease, right radius, subsequent encounter for fracture with malunion Pathological fracture in neoplastic disease, right radius, sequela Pathological fracture in neoplastic disease, left radius, initial encounter for fracture Pathological fracture in neoplastic disease, left radius, subsequent encounter for fracture with routine healing Pathological fracture in neoplastic disease, left radius, subsequent encounter for fracture with delayed healing Pathological fracture in neoplastic disease, left radius, subsequent encounter for fracture with nonunion
19 Bone Mineral Density Studies 19 M84.534P M84.534S M84.539A M84.539D M84.539G M84.539K M84.539P M84.539S M84.60xA M84.60xD M84.60xG M84.60xK M84.60xP M84.60xS M84.631A M84.631D M84.631G M84.631K M84.631P M84.631S Pathological fracture in neoplastic disease, left radius, subsequent encounter for fracture with malunion Pathological fracture in neoplastic disease, left radius, sequela Pathological fracture in neoplastic disease, unspecified ulna and radius, initial encounter for fracture Pathological fracture in neoplastic disease, unspecified ulna and radius, subsequent encounter for fracture with routine healing Pathological fracture in neoplastic disease, unspecified ulna and radius, subsequent encounter for fracture with delayed healing Pathological fracture in neoplastic disease, unspecified ulna and radius, subsequent encounter for fracture with nonunion Pathological fracture in neoplastic disease, unspecified ulna and radius, subsequent encounter for fracture with malunion Pathological fracture in neoplastic disease, unspecified ulna and radius, sequela Pathological fracture in other disease, unspecified site, initial encounter for fracture Pathological fracture in other disease, unspecified site, subsequent encounter for fracture with routine healing Pathological fracture in other disease, unspecified site, subsequent encounter for fracture with delayed healing Pathological fracture in other disease, unspecified site, subsequent encounter for fracture with nonunion Pathological fracture in other disease, unspecified site, subsequent encounter for fracture with malunion Pathological fracture in other disease, unspecified site, sequela Pathological fracture in other disease, right ulna, initial encounter for fracture Pathological fracture in other disease, right ulna, subsequent encounter for fracture with routine healing Pathological fracture in other disease, right ulna, subsequent encounter for fracture with delayed healing Pathological fracture in other disease, right ulna, subsequent encounter for fracture with nonunion Pathological fracture in other disease, right ulna, subsequent encounter for fracture with malunion Pathological fracture in other disease, right ulna, sequela
20 Bone Mineral Density Studies 20 M84.632A M84.632D M84.632G M84.632K M84.632P M84.632S M84.633A M84.633D M84.633G M84.633K M84.633P M84.633S M84.634A M84.634D M84.634G M84.634K M84.634P M84.634S M84.639A M84.639D Pathological fracture in other disease, left ulna, initial encounter for fracture Pathological fracture in other disease, left ulna, subsequent encounter for fracture with routine healing Pathological fracture in other disease, left ulna, subsequent encounter for fracture with delayed healing Pathological fracture in other disease, left ulna, subsequent encounter for fracture with nonunion Pathological fracture in other disease, left ulna, subsequent encounter for fracture with malunion Pathological fracture in other disease, left ulna, sequela Pathological fracture in other disease, right radius, initial encounter for fracture Pathological fracture in other disease, right radius, subsequent encounter for fracture with routine healing Pathological fracture in other disease, right radius, subsequent encounter for fracture with delayed healing Pathological fracture in other disease, right radius, subsequent encounter for fracture with nonunion Pathological fracture in other disease, right radius, subsequent encounter for fracture with malunion Pathological fracture in other disease, right radius, sequela Pathological fracture in other disease, left radius, initial encounter for fracture Pathological fracture in other disease, left radius, subsequent encounter for fracture with routine healing Pathological fracture in other disease, left radius, subsequent encounter for fracture with delayed healing Pathological fracture in other disease, left radius, subsequent encounter for fracture with nonunion Pathological fracture in other disease, left radius, subsequent encounter for fracture with malunion Pathological fracture in other disease, left radius, sequela Pathological fracture in other disease, unspecified ulna and radius, initial encounter for fracture Pathological fracture in other disease, unspecified ulna and radius, subsequent encounter for fracture with routine healing
21 Bone Mineral Density Studies 21 M84.639G M84.639K M84.639P Pathological fracture in other disease, unspecified ulna and radius, subsequent encounter for fracture with delayed healing Pathological fracture in other disease, unspecified ulna and radius, subsequent encounter for fracture with nonunion Pathological fracture in other disease, unspecified ulna and radius, subsequent encounter for fracture with malunion M84.639S Pathological fracture in other disease, unspecified ulna and radius, sequela M85.80 Other specified disorders of bone density and structure M85.89 M85.9 Disorder of bone density and structure, unspecified M89.9 Disorder of bone, unspecified M94.9 Disorder of cartilage, unspecified N18.3 Chronic kidney disease, stage 3 (moderate) N18.4 Chronic kidney disease, stage 4 (severe) N18.5 Chronic kidney disease, stage 5 N25.81 Secondary hyperparathyroidism of renal origin N91.0 Primary amenorrhea N91.1 Secondary amenorrhea N91.2 Amenorrhea, unspecified N91.3 Primary oligomenorrhea N91.4 Secondary oligomenorrhea N91.5 Oligomenorrhea, unspecified N95.1 Menopausal and female climacteric states N95.2 Postmenopausal atrophic vaginitis N95.8 Other specified menopausal and perimenopausal disorders N95.9 Unspecified menopausal and perimenopausal disorder T38.0x5A Adverse effect of glucocorticoids and synthetic analogues, initial encounter T38.0x5S T38.4x5A T38.4x5S T38.5x5A T38.5x5S T50.0x5A T50.0x5S Z08 Z09 Adverse effect of glucocorticoids and synthetic analogues, sequela Adverse effect of oral contraceptives, initial encounter Adverse effect of oral contraceptives, sequela Adverse effect of other estrogens and progestogens, initial encounter Adverse effect of other estrogens and progestogens, sequela Adverse effect of mineralocorticoids and their antagonists, initial encounter Adverse effect of mineralocorticoids and their antagonists, sequela Encounter for follow-up examination after completed treatment for malignant neoplasm Encounter for follow-up examination after completed treatment for
22 Bone Mineral Density Studies 22 conditions other than malignant neoplasm Z Encounter for screening for osteoporosis Z78.0 Asymptomatic menopausal state Z79.3 Long term (current) use of hormonal contraceptives Z79.51 Long term (current) use of inhaled steroids Z79.52 Long term (current) use of systemic steroids Z Long term (current) use of opiate analgesic Z Other long term (current) drug therapy V. SUPPLEMENTAL INFORMATION PRACTICE GUIDELINES AND POSITION STATEMENTS U.S. Preventive Services Task Force The USPSTF commissioned a systematic review of the evidence for osteoporosis screening. The comments below are largely derived from this review. 1. There is convincing evidence that bone measurement tests predict short-term risk for osteoporotic fractures in women and men. 2. No controlled studies have evaluated the effect of screening for osteoporosis on fracture rates or fracture-related morbidity or mortality. 3. Adequate evidence indicates that clinical risk-assessment instruments (FRAX, OST and others) have only modest predictive value for low bone density or fractures. The USPSTF derived the 9.3% value from using the FRAX tool to determine the fracture risk of an average 65-year-old white woman without other risk factors. 4. Current diagnostic and treatment criteria for osteoporosis rely on DXA measurements only; criteria for quantitative ultrasonography have not been defined. For this reason, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) of the hip and lumbar spine is generally considered the preferred test. Quantitative ultrasonography of the calcaneus is as effective as DXA in predicting fractures of the femoral neck, hip and spine and has some advantages the absence of radiation exposure, portability and lower cost. VI. Important Reminder The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.
23 Bone Mineral Density Studies 23 This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA's determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. VII. References 1. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM, AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract Nov-Dec; 16(Suppl 3): BCBSA Medical Policy Reference Manual. Bone density studies. Policy # Last review March Diagnosis of Osteoporosis in Men, Premenopausal Women, and Children. J Clin Densitom 2004 Spring; 7(1): [82 references]. 4. Hau Liu, Neil M. Paige, et.al: Screening for osteoporosis in men: A systematic review from the American College of Physicians Guideline. Ann Intern Med, May 2008; 148: Institute for Clinical Systems Improvement (ICSI). Health Care Guideline, Diagnosis and Treatment of Osteoporosis. Eighth Edition. July Institute for Clinical Systems Improvement (ICSI). Osteoporosis Screening, Level II; osteoporosis_screening/. Accessed June 16, National Osteoporosis Foundation: Clinicians Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; U.S. Preventive Services Task Force. Screening for Osteoporosis. Recommendation Statement. January Agency for Healthcare Research and Quality, Rockville, MD. 9. Ward L, et al; Bisphosphonate Therapy for Children and Adolescents with Secondary Osteoporosis. Premedline identifier Cochrane database sys rev Conference of Radiation Control Program Directors' Task Force on Bone Densitometry. Technical white paper: Bone Densitometry. October Adams J et al. Vertebral Fracture Initiative Part II Radiological Assessment of Vertebral Fracture. International Osteoporosis Foundation World Health Organization Collaborating Centre for Metabolic Bone Diseases. WHO Fracture Risk Assessment tool. Available online at U.S. Preventive Services Task Force (USPSTF). Osteoporosis: Screening. 2011;
Bone (Mineral) Density Studies
Bone (Mineral) Density Studies Policy Number: Original Effective Date: MM.05.002 03/23/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Radiology Place(s) of Service:
More informationBone Mineral Density Studies in Adult Populations
Bone Mineral Density Studies in Adult Populations Last Review Date: July 14, 2017 Number: MG.MM.RA10aC6 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationContractor Number 03201
Local Coverage Article for Bone Mass Measurements Coverage - 2012 CPT Updates (A51577) Contractor Information Contractor Name Noridian Administrative Services, LLC opens in new window Contractor Number
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A
Local Coverage Determination (LCD): Bone Mass Measurement (L36460) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
More informationWCHQ Ambulatory Measure Specification Screening For Osteoporosis Measurement Period 07/01/16-06/30/17 Submission Period: 09/05/17-10/20/17
MEASURE DESCRIPTION The percentage of women age 65 through 85 who had a minimum of one bone densitometry test at age 60 or above or have a diagnosis of osteoporosis or osteopenia. Disclaimer: Measures
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationClinical Appropriateness Guidelines: Advanced Imaging
Clinical Appropriateness Guidelines: Advanced Imaging Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry Effective Date: September 5, 2017 Proprietary Date of Origin: 05/21/2007
More informationMEDICAL POLICY SUBJECT: BONE DENSITOMETRY/ BONE DENSITY STUDIES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BONE DENSITOMETRY/ 07/20/06, 05/17/07, 06/19/08, 09/17/09, PAGE: 1 OF: 9 If the member's subscriber contract excludes coverage for a specific service it is not covered under that
More informationCpt code for bone density of hips only
Cpt code for bone density of hips only Enter a location: Find a13 This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationQuality ID #39 (NQF 0046): Screening for Osteoporosis for Women Aged Years of Age National Quality Strategy Domain: Effective Clinical Care
Quality ID #39 (NQF 0046): Screening for Osteoporosis for Women Aged 65-85 Years of Age National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationJurisdiction Nebraska. Retirement Date N/A
If you wish to save the PDF, please ensure that you change the file extension to.pdf (from.ashx). Local Coverage Determination (LCD): BONE Mass Measurement (L31620) Contractor Information Contractor Name
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bone_mineral_density_studies 12/1996 9/2017 9/2018 9/2017 Description of Procedure or Service Bone density
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationBone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?
Scan for mobile link. Bone Densitometry What is a Bone Density Scan (DXA)? Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology
More informationChiropractic ICD-10 Common Codes List
Chiropractic ICD-10 Common Codes List This is a preliminary list of Common ICD-10 Codes for chiropractic diagnoses. This is a common code list to be used as a guide for coding and is not intended to represent
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Bone Mineral Density Studies sad EFFECTIVE DATE: 06 07 2011 POLICY LAST UPDATED: 11 06 2018 OVERVIEW Bone density studies can be used to identify individuals with osteoporosis and
More informationNegative Pressure Wound Therapy (NPWT)
Negative Pressure Wound Therapy (NPWT) Policy Number: Original Effective Date: MM.01.005 11/19/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 01/01/2015 Section: DME Place(s) of Service:
More informationIEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan
Policy: IEHP UM Subcommittee Approved Authorization Guidelines IEHP considers bone mineral density testing using DEXA medically necessary for members who meet any of the following criteria: Women aged
More informationKyphoplasty and Vertebroplasty
Kyphoplasty and Vertebroplasty Policy Number: Original Effective Date: MM.06.007 01/11/2005 Line(s) of Business: Current Effective Date: HMO; PPO 02/01/2012 Section: Surgery Place(s) of Service: Inpatient;
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationLung-Volume Reduction Surgery ARCHIVED
Lung-Volume Reduction Surgery ARCHIVED Policy Number: Original Effective Date: MM.06.008 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST 03/22/2013 Section: Surgery Place(s) of
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationMEDICAL POLICY MEDICARE ADVANTAGE ONLY (See Product Variations)
Original Issue Date (Created): 11/1/2010 Most Recent Review Date (Revised): 1/18/2018 Effective Date: 9/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationPayment Policy. Chiropractic Care. Policy Specific Section: September 10, 2012 November 10, 2012
Payment Policy Chiropractic Care Type: Payment Policy Policy Specific Section: Payment Original Policy Date: Effective Date: September 10, 2012 November 10, 2012 Description Chiropractic is a branch of
More informationNational Imaging Associates, Inc. Clinical guidelines CHIROPRACTIC SERVICES. Original Date: Page 1 of FOR CMS (MEDICARE) MEMBERS ONLY
National Imaging Associates, Inc. Clinical guidelines CHIROPRACTIC SERVICES CPT4 Codes: Please refer to pages 2-10 LCD ID Number: L35424 Novitas: J-H: DC, DE, MD, NJ, PA J-L: AR, CO, LA, MS, NM, OK, TX
More informationWomen s Imaging ICD-10-CM
Women s Imaging ICD-10-CM Clinical Documentation Guides Brought to you by www.codingstrategies.com The Resource for Physician and Outpatient Coding, Compliance & ICD-10-CM OTHER CLINICAL DOCUMENTATION
More informationICD-10 Service Line Overview Musculoskeletal
ICD-10 Service Line Overview Musculoskeletal ICD-10 incorporates much greater clinical detail and specificity as well as updated terminology to be consistent with current clinical practices. ICD-10-CM
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationKyphoplasty and Vertebroplasty
Kyphoplasty and Vertebroplasty Policy Number: Original Effective Date: MM.06.007 01/11/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/27/2014 Section: Surgery Place(s)
More informationRemicade (Infliximab)
Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)
More informationBortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationOP-14: SIMULTANEOUS USE OF BRAIN COMPUTED TOMOGRAPHY (CT) AND SINUS COMPUTED TOMOGRAPHY (CT)
OP-14: SIMULTANEOUS USE OF BRAIN COMPUTED TOMOGRAPHY (CT) AND SINUS COMPUTED TOMOGRAPHY (CT) Description of Measure This measure calculates the percentage of Brain CT studies with a simultaneous Sinus
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Forteo) Reference Number: CP.PHAR.188 Effective Date: 11.15.17 Last Review Date: 02.19 Line of Business: Commercial* (Exchange Plans), HIM, Medicaid Coding Implications Revision Log See
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOne hospitalization with any of the defining diagnoses of spondylosis (see ICD9 and ICD10 code lists below) in any diagnostic position; or
1 ORTHO 16 SPONDYLOSIS Includes spondylopathies due to asymptomatic and symptomatic degenerative changes of the bony spine (M47 and M48); Does not include ankylosing spondylitis (M45), other inflammatory
More informationInsulin Pumps - External
Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of
More informationEPIDURAL STEROID AND FACET INJECTIONS FOR SPINAL PAIN
EPIDURAL STEROID AND FACET INJECTIONS FOR SPINAL PAIN UnitedHealthcare Oxford Clinical Policy Policy Number: PAIN 019.21 T2 Effective Date: October 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE...
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationNeurostimulators and Neuromuscular
Neurostimulators and Neuromuscular Stimulators Chapter.1 Enrollment..................................................................... -2.2 Benefits, Limitations, and Authorization Requirements...........................
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A
Local Coverage Determination (LCD): Chiropractic Services (L35424) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
More informationBone Mineral Densitometry with Dual Energy X-Ray Absorptiometry
Bone Mineral Densitometry with Dual Energy X-Ray Absorptiometry R Gilles, Laurentius Ziekenhuis Roermond 1. Introduction Osteoporosis is characterised by low bone mass, disruption of the micro-architecture
More informationPROFMED MEDICAL SCHEME
PROFMED MEDICAL SCHEME OPTIONS APPLICABLE: ALL OPTIONS ICD10 CODES FOR ELIGIBLE CHRONIC CONDITIONS ICD-10 codes are required when a patient's chronic condition is registered with SwiftOnline. The applicable
More informationDIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: CHAPTER 13, M CODES MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE
DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: CHAPTER 13, M CODES MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE Preferred Clinical Services for Leading Age Florida August 26-27, 2015 MUSCULOSKELETAL FUNCTIONS
More informationMedicare Regulations for Chiropractors. Presented by Clinic Pro Software Inc. Marilyn K. Gard. CEO, MBA
Medicare Regulations for Chiropractors Presented by Clinic Pro Software Inc. Marilyn K. Gard. CEO, MBA Use AT modifier which means active treatment. Claims submitted for Chiropractic manipulative treatment
More information1 of 10 5/14/15 2:48 PM
Close window Guideline Synthesis: Screening and Risk Assessment for Osteoporosis Guidelines Being Compared: 1. The North American Menopause Society (). Management of osteoporosis in postmenopausal women:
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below
More informationChiroCredit.com / OnlineCE.com presents Documentation 101 Part 4 of 10 Instructor: Paul Sherman, DC
Online Continuing Education Courses www.onlinece.com www.chirocredit.com ChiroCredit.com / OnlineCE.com presents Documentation 101 Part 4 of 10 Instructor: Paul Sherman, DC Important Notice: This download
More informationClinical Policy: Denosumab (Prolia, Xgeva) Reference Number: CP.PHAR.58
Clinical Policy: (Prolia, Xgeva) Reference Number: CP.PHAR.58 Effective Date: 03/11 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationFor more information call , or visit
Target Coding ICD-10 List for Chiropractic HEADACHE G43: Migraine G43.0: Migraine without aura (common migraine) G43.009: Migraine without aura, not intractable, without status migrainosus (migraine without
More informationICD 10 CM DOCUMENTATION TIPS & CODE EXAMPLES
WORKSHOP 2: Orthopedic / Podiatry / Spine ICD 10 CM DOCUMENTATION TIPS & CODE EXAMPLES Ready. Set. Code! ICD 10 CM by Specialty NJHA Healthcare Business Solutions ARTERIOSCLEROSIS OF EXTREMITIES When documenting
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationFORTEO (teriparatide) INJECTION
FORTEO (teriparatide) INJECTION Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationBone Density Measurement in Women
Bone Density Measurement in Women Revised 2005 Scope This guideline defines the medical necessity of bone mineral density (BMD) measurement using dualenergy x-ray absorptiometry (DXA or DEXA), and applies
More informationBevacizumab (Avastin)
Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More information[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA CCC PLUS and MEDALLIO/FAMIS 4.0 Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationOsteoporosis: Risk Factors, Diagnostic Methods And Treatment Options
ISPUB.COM The Internet Journal of Academic Physician Assistants Volume 1 Number 1 Osteoporosis: Risk Factors, Diagnostic Methods And Treatment Options K Ihrke Citation K Ihrke.. The Internet Journal of
More informationArtificial Disc Replacement, Cervical
Artificial Disc Replacement, Cervical Policy Number: Original Effective Date: MM.06.001 02/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO 11/01/2011 Section: Surgery Place(s) of Service:
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationICD-10 Common Codes per CMS
Abdominal Pain (ICD09-CM 789.00 TO 789.09 range) R10.0 Acute abdomen R10.10 Upper abdominal pain, unspecified R10.11 Right upper quadrant pain R10.12 Left upper quadrant pain R10.13 Epigastric pain R10.2
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCLINICAL CONCEPTS FOR ORTHOPEDICS. CMS Clinical Concepts
CLINICAL CONCEPTS FOR ORTHOPEDICS CMS Clinical Concepts ICD 10 LESSONS FROM OFFICE DOCUMENTATION Presented by Dr. Frankeny OUR CHALLENGE: CHANGING OUR DOCUMENTATION ICD 10 Learn the nomenclature Documenting
More informationBone Mineral Density Studies
Bone Mineral Density Studies Policy Number: 6.01.01 Last Review: 3/2019 Origination: 10/1988 Next Review: 3/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for bone
More informationSection 4. Scans and tests. How do I know if I have osteoporosis? Investigations for spinal fractures. Investigations after you break a bone
Section 4 Scans and tests How do I know if I have osteoporosis? Investigations for spinal fractures Investigations after you break a bone Investigations if you have risk factors Investigations for children
More informationINDIANA HEALTH COVERAGE PROGRAMS
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER CODE TABLES Note: Due to possible changes in Indiana Health Coverage Programs (IHCP) policy or national coding updates, inclusion of a code on the code tables
More informationContractor Information
Local Coverage Determination (LCD): Chiropractic Services (L35424) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information CONTRACTOR
More information2013 ISCD Official Positions Adult
2013 ISCD Official Positions Adult These are the Official Positions of the ISCD as updated in 2013. The Official Positions that are new or revised since 2007 are in bold type. Indications for Bone Mineral
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2015 Section: Radiology
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below
More informationNew Osteoporosis Guidelines: What you and your health provider need to know QUESTION & ANSWER
The first of the newsletters on these Qs and As should include a refresher on the Virtual Forums what they are, how they work, etc. The fact is that less than 5% of COPN members tune in for any given Forum.
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Remicade (Infliximab) MP-026-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Annual Approval Date: 9/17/2017 Revision
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationchapter Bone Density (Densitometry) RADIOPHARMACY INDICATIONS Radionuclide Localization Quality Control Adult Dose Range Method of Administration
10766-04_CH04_redo.qxd 12/3/07 3:47 PM Page 17 chapter 4 Bone Density (Densitometry) RADIOPHARMACY Radionuclide Single radionuclide: 125 I t 1/2 : 60.1 days Energies: 23 31 kev Type: EC, x, γ, accelerator
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationBone mineral density testing: Is a T score enough to determine the screening interval?
Interpreting Key Trials CME CREDIT EDUCATIONAL OBJECTIVE: Readers will measure bone mineral density at reasonable intervals in their older postmenopausal patients Krupa B. Doshi, MD, CCD Department of
More informationMEDICARE LOCAL COVERAGE DETERMINATION COMMONLY USED DIAGNOSIS CODES
MEDICARE LOCAL COVERAGE DETERMINATION COMMONLY USED DIAGNOSIS CODES Urine drug testing (UDT) provides objective information to assist clinicians in identifying the presence or absence of drugs or drug
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.
More information